1-5 of 5
Michael Palladino, Ph.D
Close
Sort by
Journal Articles

Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.

Dharminder Chauhan, PhD, Ajita Singh, Ph.D, Mohan Brahmandam, M.S, Klaus Podar, Ph.D, Teru Hideshima, M.D., Robert Schlossman, M.D., Paul Richardson, M.D., Nikhil Munshi, M.D., Michael Palladino, Ph.D, Kenneth C. Anderson, M.D.
Journal: Blood
Blood (2007) 110 (11): 2524.
https://doi.org/10.1182/blood.V110.11.2524.2524
Published: 2007
Journal Articles

Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.

Xiangao Huang, PhD, Tracey Louie, B.Sc., Maurizio Di Liberto, Ph.D., Jun Rice, Ph.D., David Jayabalan, B.Sc., Kang Zhang, B.Sc., Michael Palladino, Ph.D., Isan Chen, M.D., Peter Toogood, Ph.D, Ruben Niesvizky, M.D., Malcolm A.S. Moore, Ph.D., Selina Chen-Kiang, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 667.
https://doi.org/10.1182/blood.V110.11.667.667
Published: 2007
Journal Articles

Induction of RKIP and Inhibition of the Transcription Repressor YY1 in B-NHL by the Novel Proteasome Inhibitor NPI-0052 and Sensitization to TRAIL-Induced Apoptosis.

Eriko Suzuki, Sara Huerta-Yepez, Ph.D., Stavroula Baritaki, Ph.D., Michael Palladino, Ph.D., Benjamin Bonavida, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2391.
https://doi.org/10.1182/blood.V108.11.2391.2391
Published: 2006
Journal Articles

In Vitro and In Vivo Proteasome Activity Profiles of Bortezomib and a Novel Proteasome Inhibitor NPI-0052.

Dharminder Chauhan, PhD, Ta-Hsiang Chao, Ph.D, Laurence Catley, M.D, Benjamin Nicholson, Ph.D, Mugdha Velanker, M.S, Teru Hideshima, Ph.D, Celia Berkers, Ph.D, Huib Ovaa, Ph.D, Saskia Neuteboom, Ph.D, Michael Palladino, Ph.D, Kenneth C. Anderson, M.D
Journal: Blood
Blood (2005) 106 (11): 3363.
https://doi.org/10.1182/blood.V106.11.3363.3363
Published: 2005
Journal Articles

A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.

Dharminder Chauhan, Ph.D, Guilan Li, M.S, Klaus Podar, Ph.D, Teru Hideshima, Ph.D, Reshma Shrigarpure, Ph.D, Laurence Catley, M.D, Constantine Mitsiades, Ph.D, Nikhil Munshi, M.D, Robert Sclossman, M.D, Rena Bahjat, Ph.D, Saskia Neuteboom, M.D., Paul Richardson, M.D, Michael Palladino, Ph.D, Kenneth C. Anderson, M.D
Journal: Blood
Blood (2004) 104 (11): 2405.
https://doi.org/10.1182/blood.V104.11.2405.2405
Published: 2004